Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21

Articles

51039 items
12:00 AM, Jul 06, 2000  |  BC Extra | Company News

Aronex amends NDA for Atragen

ARNX submitted to the FDA an amendement to its NDA for Atragen injectable all-trans retinoic acid to treat acute promyelocytic leukemia (APL). The original NDA was filed in December 1998, and in September 1999 the...
12:00 AM, Jul 06, 2000  |  BC Extra | Company News

Lexicon deal with Howard Hughes

LEXG will provide to Howard Hughes (Chevy Chase, Md.) custom knockout mice and mice developed using mouse embryonic stem (ES) cells from the public portion of LEXG's OmniBank database....
12:00 AM, Jul 06, 2000  |  BC Extra | Company News

Motorola biochip deal with SurModics

MOT received exclusive rights to SRDX's PhotoLink surface modification technology for use in nucleic acid and protein biochips. SRDX also will supply MOT with chemical reagents for biochip production, and the companies will collaborate on...
12:00 AM, Jul 06, 2000  |  BC Extra | Financial News

Arrow raises 11.1 million in venture capital

The anti-infectives company Arrow Therapeutics (London, U.K.) raised 11.1 million ($16.8 million). GIMV invested 2.75 million; Alta Partners, TVM, and 3i each invested 2.25 million; Northern Venture Managers invested 1million; and existing investors including Unibio...
12:00 AM, Jul 06, 2000  |  BC Extra | Company News

PEB files suit against Affymetrix

PE Biosystems filed suit in the U.S. District Court for the District of Delaware alleging that AFFX infringed 5 PEB patents (U.S. Patents Nos. 4,458,066; 4,500,707; 5,132,418; 5,153,319; and 4,973,679) covering preparations and processes used...
12:00 AM, Jul 05, 2000  |  BC Extra | Company News

Cell Pathways to market Aventis' Nilandron

CLPA obtained rights to market AVE's Nilandron nilutamide to urologists in the U.S. and Puerto Rico to treat prostate cancer. CLPA will receive a percentage of sales....
12:00 AM, Jul 05, 2000  |  BC Extra | Company News

Biogen returns hedgehog rights to Ontogeny

BGEN returned to Ontogeny the rights to develop and commercialize products from hedgehog proteins, a class of human proteins that induce the formation and regeneration of tissues. Ontogeny ( Cambridge, Mass.), which said BGEN's reasons...
12:00 AM, Jul 05, 2000  |  BC Extra | Company News

ML Labs licenses Clickhaler in Canada

Schein Pharmaceuticals Canada (SHP) obtained from ML Laboratories (LSE:MLB) exclusive marketing and distribution rights in Canada to use Clickhaler, a dry powder drug delivery system, with a range of asthma drugs. Innovata Biomed, an MLB...
12:00 AM, Jul 05, 2000  |  BC Extra | Company News

AmBisome gets expanded label

Gilead (GILD) and partner Fujisawa (Deerfield, Ill.) received FDA marketing approval for AmBisome amphotericin B for the treatment of cryptococcal meningitis in HIV-infected patients. Fujisawa submitted a supplemental NDA requesting a label expansion in July...
12:00 AM, Jul 05, 2000  |  BC Extra | Company News

Immunex licenses cancer antigens from UroCor

IMNX licensed rights to cancer-derived antigens from UCOR's library of genes expressed in neoplastic or pre-cancerous prostate cells. IMNX will use the antigens to develop therapeutic monoclonal antibodies to treat prostate cancer. IMNX, which will...

Pages